Targets › MERTK
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Dec 2026.
Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to several ligands including LGALS3, TUB, TULP1 or GAS6. Regulates many physiological processes including cell survival, migration, differentiation, and phagocytosis of apoptotic cells (efferocytosis). (UniProt, Q12866)
Open in Phaseline: the race on MERTK, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Emory University | MRX-2843 FLT3/MerTK inhibitor | FLT3, MERTK | Phase 1 | Advanced Lung Non-Small Cell Carcinoma | Dec 2026 |
Advanced Lung Non-Small Cell Carcinoma (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.